Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
College of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1367-1376. doi: 10.1016/j.numecd.2023.04.012. Epub 2023 Apr 15.
To determine trends in lipid profiles and lipid control in US adults with diabetes and assess variation in these trends across sex and race/ethnicity from 2007 to 2018.
Serial cross-sectional analysis of data from diabetic adults participating in the National Health and Nutrition Examination Survey (NHANES; 2007-2008 to 2017-2018). Among the 6116 participants included (weighted mean age, 61.0 years; 50.7% men), age-adjusted TC (p for trend < 0.001), LDL-C (p for trend < 0.001), TG (p for trend = 0.006), TG/HDL-C (p for trend = 0.014) and VLDL-C (p for trend = 0.015) decreased significantly. Age-adjusted LDL-C levels were consistently higher in women than in men over the study period. Age-adjusted LDL-C improved significantly for diabetic whites and blacks but did not change significantly for the other races/ethnicity. Lipid parameters improved for non-coronary heart disease (CHD) diabetic adults, except for HDL-C, while no lipid parameter significantly changed for diabetic adults with concomitant CHD. Among diabetic adults receiving statin therapy, age-adjusted lipid control remained unchanged from 2007 to 2018, as did adults with concomitant CHD. However, age-adjusted lipid control improved significantly for men (p for trend < 0.01) and diabetic Mexican Americans (p for trend < 0.01). In 2015-2018, female diabetic participants receiving statins had lower odds of achieving lipid control (OR: 0.55; 95% CI: 0.35-0.84; P = 0.006) than men. Differences in lipid control across different races/ethnicities no longer existed.
Lipid profiles improved in the US adults with diabetes from 2007 to 2018. Although rates of lipid control did not improve nationally in adults receiving statins, these patterns varied by sex and race/ethnicity.
本研究旨在确定美国糖尿病患者的血脂谱变化趋势,并评估 2007 年至 2018 年期间性别和种族/民族差异对这些趋势的影响。
本研究对参与国家健康和营养检查调查(NHANES;2007-2008 年至 2017-2018 年)的糖尿病成年人进行了一系列横断面分析。在纳入的 6116 名参与者中(加权平均年龄为 61.0 岁,50.7%为男性),TC(趋势 P 值<0.001)、LDL-C(趋势 P 值<0.001)、TG(趋势 P 值=0.006)、TG/HDL-C(趋势 P 值=0.014)和 VLDL-C(趋势 P 值=0.015)显著下降。研究期间,女性的 LDL-C 水平始终高于男性。糖尿病白人和黑人的 LDL-C 水平显著改善,但其他种族/民族的 LDL-C 水平没有显著变化。非冠心病(CHD)糖尿病成年人的血脂参数有所改善,除了 HDL-C 外,而同时患有 CHD 的糖尿病成年人的血脂参数没有显著变化。在接受他汀类药物治疗的糖尿病成年人中,2007 年至 2018 年期间,年龄调整后的血脂控制保持不变,同时患有 CHD 的成年人也是如此。然而,男性(趋势 P 值<0.01)和墨西哥裔美国人(趋势 P 值<0.01)的年龄调整后血脂控制显著改善。2015-2018 年,服用他汀类药物的女性糖尿病患者达到血脂控制目标的可能性低于男性(OR:0.55;95%CI:0.35-0.84;P=0.006)。不同种族/民族之间的血脂控制差异不再存在。
2007 年至 2018 年,美国糖尿病患者的血脂谱有所改善。尽管服用他汀类药物的成年人全国范围内的血脂控制率没有提高,但这些模式因性别和种族/民族而异。